Downloaded 409 times
Uploaded byPriyesh Waghmare
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical company headquartered in London, UK. It is the 3rd largest pharmaceutical company by revenue and has leading market share in anti-infectives, central nervous system, respiratory, and gastrointestinal drugs. GSK spends over $450,000 per hour on research and development and has acquired several companies in recent years to expand its product portfolio. The company's business model focuses on several therapeutic areas with respiratory, central nervous system, and vaccines being the largest segments by revenue.
More Related Content
GlaxoSmithKline
- 1.
- 2. INTRODUCTION •Global pharmaceutical, biologics,vaccines and consumer healthcare company •3rd largest pharmaceutical company in the world based on revenues •Leading market share in 4 of the 5 largest therapeutic markets-- anti- infective , central nervous system, respiratory, and gastro- intestinal/metabolic. •5 % of the global pharmaceuticals market. •1,100 prescriptions are written for one of its products every minute. •Spends over $450,000 every hour on R & D.
- 3. COMPANY PROFILE •Headquarters: London,UK •Employee Strength: 96,500 •Global operations: Over 100 countries •Stock Listing: Primary - London Stock Exchange Secondary – New York Stock Exchange •Revenue (2010): £ 28.4 billion
- 5. COMPANY EVOLUTION GlaxoWellcome SmithKline Beecham • Beecham Pills laxative in England • In 1880, Burroughs Wellcome & gave birth to the Beecham Group Company was founded in London – in 1843. • Smith, Kline & Co founded in research in animal health 1875 – pure research • Glaxo was founded in Bunnythorpe, • 1989 merged with Beecham to form SmithKline Beecham plc. New Zealand in 1904 – baby food producer • Burroughs Wellcome and Glaxo merged in 1995 to form GlaxoWellcome
- 7. RECENT ACQUISITIONS • In2001 it completed its purchase of New Jersey-based Block Drug. • On 16 November 2009 the US FDA announced that a vaccine for 2009 H1N1 influenza protection (manufactured by GSK's ID Biomedical Corp. subsidiary) would join the four approved vaccines. • In November 2009 GlaxoSmithKline (85%) formed a joint venture with Pfizer (15%) to create ViiV Healthcare for HIV based drugs. • In June 2010, the company acquired Laboratorios Phoenix for $253m, which is an Argentine pharmaceutical company focused on the development, marketing and sale of branded generic products. • In December 2010, GSK announced its acquisition of the sports nutrition company Maxinutrition.
- 8.
- 9. GSK Medicinal Products TherapeuticArea Turnover 2010 £m Respiratory 7,238 Central nervous system 1,753 Anti-viral 1,086 Anti-bacterials 1,396 Metabolic 678 Vaccines 4,326 Oncology and emesis 688 Cardiovascular and 2,570 urogenital Dermatologicals 1,087 Other 994 Total 21,816
- 10. Bexxar • Drug forthe treatment of follicular lymphoma • Drug combination is manufactured by Corixa • Received US Food and Drug Administration approval in mid- 2003 • GlaxoSmithKline acquired Corixa in mid-2005 • Charges - $30,000 dollars a treatment • Currently involved in 9 EU clinical trials testing efficacy and safety ranging from phase III to phase I
- 11. Lexiva • HIV proteaseinhibitor • Co-developed the drug with Vertex Pharmaceuticals Incorporated. • U.S. Approval: 2003 • Got approval in EU market in July 2004. • Marketed as Telzir EU at approx £9/unit • Lexiva global sales in 2010 were £155 million
- 12. Cervarix • Treatment againstHuman Papillomaviruses (HPV) infection • European Approval in September 2007 • FDA approval October 2009 • Approved and marketed in 99 countries including most of the major markets like US, Europe, Japan, China, India, Brazil, South Africa • Cervarix global sales in 2010 were £242 million
- 13. GSK Biopharmaceuticals • Astrategic unit within GSK’s Global Manufacturing & Supply network • Located in Philadelphia, USA; Parma, Italy and Barnard Castle, UK. • Undertakes Contract manufacturing partner • FDA and European licensed multi-product facilities.
Editor's Notes
- #3 GlaxoSmithKline plc (GSK) was formed from the December 2000 merger of GlaxoWellcome plc and SmithKline Beecham plc. The $70 billion deal created the world's largest drug manufacturer and research-based pharmaceutical concern. The combined entity controlled leading market share in four of the five largest therapeutic markets--anti-infectives, central nervous system, respiratory, and gastro-intestinal/metabolic. Overall, the firm controlled nearly seven percent of the global pharmaceuticals market. Its product line includes antibiotic, antidepressant, gastrointestinal, dermatological, respiratory, cancer, and cardiovascular medications. GSK claims that every minute of every day, more than 1,100 prescriptions are written for one of its products. The company has one of the largest research and development divisions in the drug industry and spends over $450,000 every hour to research new medicine.
- #6 GlaxoSmithKline plc (GSK) was formed from the merger of GlaxoWellcome plc and SmithKline Beecham plc (December 2000). GlaxoWellcomeIn 1880, Burroughs Wellcome & Company was founded in London by American pharmacists Henry Wellcome and Silas Burroughs.[5] The Wellcome Tropical Research Laboratories opened in 1902.[5] In 1959 the Wellcome Company bought Cooper, McDougall & Robertson Inc. to become more active in animal health.[5] The Wellcome Company production centre was moved from New York to North Carolina in 1970 and the following year another research centre was built.Glaxo was founded in Bunnythorpe, New Zealand in 1904.[5] Originally Glaxo was a baby food manufacturer processing local milk into a baby food by the same name: the product was sold in the 1930s under the slogan "Glaxo builds bonny babies". Still visible on the main street of Bunnythorpe is a derelict dairy factory (factory for drying and processing cows' milk into powder) with the original Glaxo logo clearly visible, but nothing to indicate that this was the start of a major multinational company.Glaxo became Glaxo Laboratories, and opened new units in London in 1935.[5] Glaxo Laboratories bought two companies, Joseph Nathan and Allen & Hanburys, in 1947 and 1958 respectively.[5] After the Company bought Meyer Laboratories in 1978,[5] it started to play an important role in the US market. In 1983 the American arm Glaxo Inc. moved to Research Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North Carolina. Burroughs Wellcome and Glaxo merged in 1995 to form GlaxoWellcome.[5] In the same year, GlaxoWellcome opened its Medicine Research Centre inStevenage.[5] Three years later GlaxoWellcome bought Polfa Poznan Company in Poland.[5][edit]SmithKline BeechamIn 1843, Thomas Beecham launched his Beecham's Pills laxative in England giving birth to the Beecham Group.[5]Beechams opened its first factory in St Helens, Lancashire, England for rapid production of medicines in 1859. By the 1960s it was extensively involved in pharmaceuticals.The GSK Headquarters in BrentfordIn 1830, John K. Smith opened its first pharmacy in Philadelphia.[5] In 1865 Mahlon Kline joined the business which, 10 years later, became Smith, Kline & Co.[5] Subsequently, in 1891, it merged with French, Richard and Company.[5] It changed its name to Smith Kline & French Laboratories as it focused more on research in 1929. Years later, Smith Kline & French Laboratories opened a new laboratory in Philadelphia; it then bought Norden Laboratories, a business doing research into animal health.Smith Kline & French Laboratories bought Recherche et IndustrieThérapeutiques (Belgium) in 1963 to order to focus on vaccines.[5] The Company started to expand globally buying seven laboratories in Canada and the US in 1969. In 1982, it bought Allergan, a manufacturer of eye and skincare products.[5] The Company merged with Beckman Inc. later that year and then changed its name to SmithKline Beckman.[5]In 1988, SmithKline Beckman bought its biggest competitor, International Clinical Laboratories,[5] and in 1989 merged with Beecham to form SmithKline Beecham plc.[5] The headquarters of the Company were then moved to England. To expand research & development in the US, SmithKline Beecham bought a new research center in 1995. Another new research centre at New Frontiers Science Park in Harlow was opened in 1997.[5]In 2000, GlaxoWellcome and SmithKline Beecham merged to form GlaxoSmithKline.[6][edit]Recent developmentsIn 2001 it completed its purchase of New Jersey-based Block Drug.[7]On 16 November 2009 the US Food and Drug Administration (FDA) announced that a vaccine for 2009 H1N1 influenza protection (manufactured by GSK's ID Biomedical Corp. subsidiary) would join the four vaccines approved on 15 September.[8]In June 2010, the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company focused on the development, marketing and sale of branded generic products, for a cash consideration of approximately $253m.[9]In December 2010, GSK announced its acquisition of the sports nutrition company Maxinutrition.[10
- #13 Cervarix is a protein sub-unit vaccine intended to protect females against the diseases caused by infection with Human Papillomaviruses (HPV)These diseases include: - cervical cancer - precancerous cervical lesions
- #14 US Biopharmaceuticals: Our United States facility, located in suburban Philadelphia, is a state of the art facility, providing contract manufacturing services focused on bulk biopharmaceuticals derived from mammalian cell culture since 1999. Barnard Castle: Barnard Castle was established in 1945. Dose forms include liquid inhalations, sterile liquids, topicals, antibiotics in tablet and suspension. BioCTL (Stevenage, UK): Our Biopharm Central Testing Laboratory (BioCTL) is responsible for commercial product release, testing of Drug Substance and Product, key assays and stability testing. It is also responsible of critical reagent and commercial reference standard control, testing and storage.Parma: The GSK Italy Parma site is a worldwide supplier of sterile ampoules and vials, freeze-dried products in vials, nasal sprays and solid oral products.GlaxoSmithKline Biopharmaceuticals is a full-service contract manufacturing partner in the development and manufacture of cGMP biopharmaceutical proteins for clinical trials and commercial use. We offer FDA and European licensed multi-product facilities. Our featured services include the low-cost, rapid scale-up and manufacture of mammalian cell-derived proteins at up to 5,000 litre scale and the preparation of formulated bulk products. We also offer fill finish for sterile liquids and freeze dried drug products. Our services also include complete analytical and regulatory services to speed technical transfer and regulatory approval.. GSK Biopharmaceuticals is a strategic unit within GSK’s Global Manufacturing & Supply network. With bulk manufacturing sites (US and the UK), secondary filling (UK and Italy) and a central testing lab (UK), we have the experience, knowledge, resources and corporate backing to satisfy all of your requirements for reliable, cost-effective, and high-quality biopharmaceutical contract manufacturing services.